Clinical Research Directory
Browse clinical research sites, groups, and studies.
Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients
Sponsor: Leiden University Medical Center
Summary
The aim of the study is to perform a clinical validation of the analytical method for dried blood spot microsampling of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib, abiraterone, enzalutamide, nivolumab, ipilimumab, pembrolizumab, atezolizumab, bevacizumab or enfortumab vedotin. The secondary objective is to test the feasibility of home monitoring (microsampling TDM) of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib, abiraterone, enzalutamide, nivolumab, ipilimumab, pembrolizumab, atezolizumab, bevacizumab or enfortumab vedotin in oncology patients.
Official title: Microsampling to Facilitate Drug Monitoring of Oncolytics
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
360
Start Date
2025-10-06
Completion Date
2028-07-01
Last Updated
2025-11-21
Healthy Volunteers
No
Conditions
Interventions
Therapeutic drug monitoring with a dried blood spot and microatainer.
Patients who use an oral oncolytic will be asked to provide four paired whole blood (WB) samples obtained by venapuncture.
Locations (1)
Leiden University Medical Center
Leiden, South Holland, Netherlands